

## **Press Release**

Zug, 26 July 2011

Following the successful sales of its investments in PharmaSwiss and mtm laboratories, HBM BioVentures Ltd has decided to stop delegating the implementation of its share buy-back programme to Bank Sarasin & Cie Ltd. As a result, HBM BioVentures will no longer be permitted to repurchase shares during blackout periods. The share buy-back programme was approved by the Ordinary Shareholders' Meeting of HBM BioVentures on 4 September 2009. The company began delegating its implementation to Bank Sarasin in June 2010 to prevent potential lengthy interruptions to the programme.

This change does not affect the mandate of Bank Sarasin for the execution of transactions under the share buy-back programme. Bank Sarasin will thus continue to input the bid prices on the second trading line for HBM BioVentures (ticker: HBMNE).

For further information, please contact Dr. Joachim Rudolf, CFO of HBM BioVentures Ltd., tel.:+41 41 768 11 08, [joachim.rudolf@hbmbioventures.com](mailto:joachim.rudolf@hbmbioventures.com).

### **Brief profile of HBM BioVentures Ltd**

HBM BioVentures is invested globally in some 25 mature companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of many companies in HBM BioVentures' portfolio are either at an advanced stage of development or already available on the market. The investment focus currently is on follow-on financing for still-private companies in the portfolio that offer high value-creation potential. HBM BioVentures is an interesting alternative to investments in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

### **Disclaimer**

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German

**NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA**



Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

**HBM BioVentures Ltd**  
Bundesplatz 1  
CH-6300 Zug / Switzerland  
Tel:+41 41 768 11 08  
Fax:+41 41 768 11 09  
[info@hbmbioventures.com](mailto:info@hbmbioventures.com)  
[www.hbmbioventures.com](http://www.hbmbioventures.com)